It treats dyslipidemia by inhibiting diacylglycerol acetyltransferase-2 (DGAT-2i), increasing acylation of fatty acids, reducing TG creation, and degrading additional ApoB, further lowering LDL levels [49]. The gene discussed is APOB; the disease is metabolic syndrome.